FDA fast tracks SAR402663 intravitreal gene therapy for wet AMD
By:Anthony DeFino Fact checked by: Christine Klimanskis, ELS Key takeaways: SAR402663 is a one-time intravitreal gene therapy designed to reduce treatment burden. It is currently being investigated in a phase…